｜Kwon Kyu-chan, CEO of Dx&Vx
｜Providing genetic analysis services for the entire life cycle and strengthening R&D expertise
｜Speeding up the development of new microbiome drugs and acquired Avixgen in April
“Our goal is to double our global sales in a year and secure at least three late-stage clinical development pipelines (new drug candidates) in three years. We want to become a company whose market capitalization is KRW 1 trillion as soon as possible. We’ll become a company that people want to work at and a company that has gained global recognition beyond just a good reputation.”
Kwon Kyu-chan, CEO of Dx&Vx (DXVX), is regarded as a drug development expert with years of experience in biological research and global regulatory affairs (RA) at Daewoong Pharmaceutical and Hanmi Pharmaceutical. Mr. Kwon has spearheaded the efforts to gaining more than a hundred global drug marketing approvals, including the US Food and Drug Administration (FDA) approvals for Hanmi Pharm’s Rolvedone, a new biological drug in the field of anti-cancer treatment, and Esomezole for gastroesophageal reflux disease treatment.
Mr. Kwon joined Dx&Vx this past May as the President of R&D and was appointed as the CEO in August. With his expertise in business development (BD) and R&D, Mr. Kwon will drive the company’s growth alongside CEO Lee Yong-gu, a global sales expert.
Dx&Vx, armed with excellent diagnostic technology, has been strengthening its drug development capabilities since Mr. Kwon joined the company.